DBV Technologies S.A. 8-K

What Happened
DBV Technologies S.A. announced that its Board (following the Compensation Committee recommendation) approved the DBV Technologies 2026 Performance Share Unit Plan and granted 4,060,000 performance share units (PSUs) to CEO Daniel Tassé. The Board approved the Plan on June 3, 2026 and the PSU grant date is June 5, 2026. Each PSU is a conditional right to one ordinary share, with vesting linked to specified regulatory milestones for Viaskin Peanut (VP) and continued employment.

Key Details

• Grant: 4,060,000 PSUs to CEO Daniel Tassé (grant date June 5, 2026).
• Performance conditions: Vesting tied to FDA BLA approvals for Viaskin Peanut — 2,900,000 PSUs become eligible upon the first FDA approval; 1,160,000 PSUs become eligible upon a second FDA approval (or all PSUs if a single BLA covers both age groups).
• Timing and forfeiture: PSUs not satisfying the performance conditions by July 1, 2028 are canceled. Vested shares will be delivered in four installments (25% each) on July 1, 2028; Jan 1, 2029; July 1, 2029; and Jan 1, 2030.
• Employment and other rules: Vesting also requires continuous employment through the vesting date (with exceptions for death, Disability, qualifying retirement, or termination without Cause/for Good Reason). On a Change in Control, performance conditions are deemed met but continued employment still applies. U.S. tax deferral (Section 409A) may delay payments for specified employees by six months.

Why It Matters
This award ties the CEO’s compensation directly to regulatory success for Viaskin Peanut, signaling management’s incentive to achieve FDA approvals. If fully vested, the grant could result in issuance of up to 4,060,000 ordinary shares (or equivalent cash in some circumstances), which is a concrete potential source of share issuance for investors to monitor. The July 1, 2028 deadline means the grant is explicitly linked to near- to mid-term regulatory outcomes rather than open-ended performance targets. Finally, vesting remains contingent on continued employment and contains tax-timing provisions that could affect when any shares or cash are actually delivered.